Anti-EGFR/EGFRVIII CAR-T cell therapy (Carsgen Therapeutics)

N/A

Report date: 2024/01/25 09:17:21

Base Information

Drug NameAnti-EGFR/EGFRVIII CAR-T cell therapy (Carsgen Therapeutics)
Drug Alias NameEGFR/EGFRvIII CAR-TCSG-EGFRCAR-EGFR/EGFRvIII T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-EGFRvIII
TargetsEpidermal growth factor receptor variant III
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesCarsgen Biomedicine (Shanghai) Co LtdRenji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRenji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
Active IndicationsN/A
Inactive IndicationsGlioma

Other Information

ATC CodeN/A
Related LinksN/A